Vimarsana
Biggest News Aggregation in the World

Page 7 - Scott Struthers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scott Struthers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scott Struthers Today - Breaking & Trending Today

Evercore ISI Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $48.00 - Vimarsana News

Evercore ISI Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $48.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price target upped by Evercore ISI from $41.00 to $48.00 in a research report issued to clients and investors on Monday, FlyOnTheWall reports. Evercore ISI’s target price would indicate a potential upside of 200.56% from the company’s previous close. A number of other research firms also […]

Daily Oral Paltusotine Maintains Acromegaly Treatment Benefit in Phase 3 Trial - Vimarsana News

Daily Oral Paltusotine Maintains Acromegaly Treatment Benefit in Phase 3 Trial

Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy.

Crinetics releases solid results for rare disease drug - The San Diego Union-Tribune - Vimarsana News

Crinetics releases solid results for rare disease drug - The San Diego Union-Tribune

If approved by the FDA, Paltusotine would be the company's first drug on the market. It treats a rare disorder caused by a tumor on a person's pituitary gland that causes the release of too much growth hormone.

Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated by Analysts at Oppenheimer - Vimarsana News

Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $40.00 price objective on the stock. A number of other research firms have also recently issued reports on CRNX. Robert W. Baird reduced their […]

Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $33.00 Price Target at HC Wainwright - Vimarsana News

Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $33.00 Price Target at HC Wainwright

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target cut by HC Wainwright from $35.00 to $33.00 in a research note released on Wednesday morning, MarketBeat Ratings reports. The firm currently has a buy rating on the stock. A number of other equities analysts also recently commented on CRNX. JMP Securities boosted their price […]